Viatris
VTRS
$0.30 (-1.85%)
1D
1W
3M
1Y
5Y
ALL
Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 12 days ago • VTRS
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Zacks Investment Research • 14 days ago • VTRS
Here's Why Viatris (VTRS) is a Strong Value Stock
Zacks Investment Research • 29 days ago • VTRS
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
Zacks Investment Research • about a month ago • VTRS
Here's Why Viatris (VTRS) is a Strong Momentum Stock
PRNewsWire • about a month ago • VTRS
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.